Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sanofi has struck a licensing deal potentially worth more than $2 billion with Skyhawk Therapeutics, betting that the biotech's RNA-targeting technology can be…
Sanofi is the latest Big Pharma to buy into RNA-targeting small-molecule drugs, agreeing to pay up to $2 billion in biobucks for access to Skyhawk…
Sanofi has entered an exclusive worldwide collaboration agreement with Skyhawk Therapeutics to discover and develop novel small molecule RNA-splicing…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Sanofi and Skyhawk Therapeutics announced an exclusive worldwide collaboration to discover and develop novel small molecule RNA-splicing modulators for challenging oncology and immunology targets. Sanofi paid $54M upfront with potentially over $2B in aggregate development, regulatory and commercial milestones plus royalties.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Skyhawk Therapeutics Inc. (this deal) | 2022 | $2.1B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2022 deals · Sanofi SA deals · Immunology deals